Physician profile
An Cao
NPI 1760945661
$2,749.54
in general payments reported to CMS, 2019-2025
27 companies · $1,945 in 2025
The $1,945 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $374 · 2022: $96.50 · 2024: $334 · 2025: $1,945.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,278.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $538.62 | 2021-2025 | |
| Ucb, INC. | $289.31 | 2025 | Fintepla, Nayzilam, Briviact |
| Biogen, INC. | $269.76 | 2022-2025 | Tysabri, Skyclarys, Vumerity |
| Genentech USA, INC. | $202.66 | 2024-2025 | Ocrevus Zunovo |
| Abbvie INC. | $176.64 | 2025 | |
| Argenx US, INC. | $154.76 | 2025 | Vyvgart Hytrulo |
| Neurocrine Biosciences, INC. | $139.22 | 2025 | |
| Sk Life Science, INC. | $133.19 | 2025 | |
| Livanova USA, INC. | $115.27 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Pfizer INC. | $108.71 | 2025 | |
| Neurelis, INC. | $80.81 | 2025 | Valtoco |
| Emd Serono, INC. | $73.49 | 2025 | |
| Catalyst Pharmaceuticals, INC. | $70.77 | 2025 | |
| Alexion Pharmaceuticals, INC. | $57.17 | 2021 | |
| Vanda Pharmaceuticals INC. | $56.89 | 2025 | Ponvory |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $44.92 | 2025 | |
| Xeris Pharmaceuticals, INC. | $37.21 | 2025 | Keveyis |
| Aucta Pharmaceuticals, INC. | $34.07 | 2025 | Motpoly Xr |
| Axsome Therapeutics, INC. | $24.62 | 2025 | Symbravo |
| Lundbeck LLC | $24.43 | 2025 | Vyepti |
| Lilly USA, LLC | $21.41 | 2025 | Kisunla |
| Csl Behring | $19.30 | 2025 | Hizentra |
| Eisai INC. | $18.41 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $16.48 | 2025 | Dysport |
| Takeda Pharmaceuticals U.S.A., INC. | $14.19 | 2025 | Hyqvia |
| Acadia Pharmaceuticals INC | $13.75 | 2025 | Nuplazid |
| Mdd US Operations, LLC | $13.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw An Cao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.